TrialBlood cancer journal2017

Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis.

K Suzuki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.